logo

Checkpoint Therapeutics, Inc. (CKPT)



Trade CKPT now with
  Date
  Headline
9/17/2020 6:41:55 AM Checkpoint Therapeutics Report Updated Interim Results From Phase 1 Clinical Trial Of Cosibelimab
11/22/2019 5:18:37 AM CKPT Prices Offering At $1.27/Shr
3/15/2019 7:38:47 AM Checkpoint Therapeutics FY Loss Attributable To Holders $36.4 Mln Or $1.27/Shr Vs Loss $22.7 Mln Or $1.00/Shr Last Year
11/2/2018 8:10:06 AM Checkpoint Therapeutics Q3 Loss Attributable To Holders $9.3 Mln Or $0.32/Shr Vs Loss Of $5.9 Mln Or $0.26/Shr Last Year
10/16/2018 8:05:29 AM Checkpoint Therapeutics Appoints Christian Béchon To Board Of Directors
9/25/2018 8:05:54 AM Checkpoint Therapeutics Announces Presentation Of Updated Data From Phase 1/2 Trial Of EGFR Inhibitor CK-101
9/6/2018 7:32:48 AM Checkpoint Therapeutics Says Encouraging Safety And Efficacy Data From Phase 1/2 Clinical Trial Of EGFR Inhibitor CK-101
8/13/2018 8:11:00 AM Checkpoint Therapeutics Announces Clinical Data On EGFR Inhibitor CK-101 Selected For Late-Breaking Oral Presentation